N-(2-aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide [ MG0103,MG 0103,MG 4230,MG 4915,MG 5026,MG-0103,MG-4230,MG-4915,MG-5026,MG4230,MG4915,MG5206,MGCD 0103,MGCD-0103,MGCD0103,mocetinostat ] undergoing phase II clinical trials for treatment of cancer